Atossa Genetics Inc. (ATOS) financial statements (2021 and earlier)

Company profile

Business Address 107 SPRING STREET
SEATTLE, WA 98104
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments40979131517
Cash and cash equivalents40979131517
Restricted cash and investments0000000
Prepaid expense2111101
Other current assets1000000
Other undisclosed current assets1011110
Total current assets:43111012141618
Noncurrent Assets
Operating lease, right-of-use asset0000000
Property, plant and equipment0000000
Intangible assets, net (including goodwill) 000 00
Intangible assets, net (excluding goodwill) 000 00
Other noncurrent assets0000000
Other undisclosed noncurrent assets0   0  
Total noncurrent assets:0000000
TOTAL ASSETS:43111012141719
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3221111
Accounts payable2110010
Accrued liabilities0000000
Employee-related liabilities1110111
Debt    000
Other liabilities0000000
Other undisclosed current liabilities13000   
Total current liabilities:16221121
Noncurrent Liabilities
Long-term debt and lease obligation 000000
Operating lease, liability 000000
Other undisclosed noncurrent liabilities (0)(0)(0)   
Total noncurrent liabilities: 000000
Total liabilities:16221121
Stockholders' equity
Stockholders' equity attributable to parent, including:2710811131518
Preferred stock0000000
Common stock9222222
Additional paid in capital130112108106106105104
Accumulated deficit(112)(104)(101)(97)(94)(91)(88)
Other undisclosed stockholders' equity attributable to parent11     
Total stockholders' equity:2710811131518
TOTAL LIABILITIES AND EQUITY:43111012141719

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Operating expenses(4)(4)(4)(3)(3)(3)(7)
Operating loss:(4)(4)(4)(3)(3)(3)(7)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
000(0)(0)00
Loss from continuing operations before equity method investments, income taxes:(4)(3)(4)(3)(3)(3)(7)
Other undisclosed loss from continuing operations before income taxes(3)      
Net loss attributable to parent:(7)(3)(4)(3)(3)(3)(7)
Other undisclosed net loss available to common stockholders, basic(5)      
Net loss available to common stockholders, diluted:(12)(3)(4)(3)(3)(3)(7)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net loss:(7)(3)(4)(3)(3)(3)(7)
Comprehensive loss, net of tax, attributable to parent:(7)(3)(4)(3)(3)(3)(7)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: